文献速递前列腺癌

靶向转移性激素敏感性前列腺癌:化学激素治疗与新型联合方案

Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
PubMed 文献 · J Urol · 2019-01-01

本文综述了截至2018年1月的文献,聚焦于转移性激素敏感性前列腺癌(mHSPC)中联合治疗的最新试验与机制。CHAARTED和STAMPEDE研究显示雄激素剥夺治疗(ADT)联合多西他赛可带来生存获益并延长进展至去势抵抗的时间;STAMPEDE的阿比特龙组和LATITUDE试验显示ADT联合阿比特龙改善总生存和无进展生存。结论认为联合治疗已成为mHSPC的标准治疗,理想方案需结合患者整体健康和合并症状况个体化选择。

要点

  • ADT联合多西他赛在CHAARTED和STAMPEDE研究中显示生存获益并延长至去势抵抗时间。
  • STAMPEDE阿比特龙组和LATITUDE试验显示ADT联合阿比特龙改善总生存和无进展生存。
  • 联合治疗已成为mHSPC标准治疗,方案需个体化权衡整体健康和合并症。

核心结论

  • 联合治疗已发展为转移性激素敏感性前列腺癌的标准治疗。
  • 理想联合方案应在个体化咨询后,结合患者整体健康和合并症状况进行选择。

研究设计与样本

  • 综述检索PubMed和Web of Science数据库截至2018年1月的同行评议文献,关键词包括转移性激素敏感性前列腺癌、多西他赛、阿比特龙和癌症衰老。
  • 同时查询ClinicalTrials.gov上正在进行的试验,并评估近期在泌尿外科和肿瘤内科主要会议上公布的相关数据。

主要发现

  • CHAARTED和STAMPEDE研究显示ADT联合化疗可带来生存获益,并延长进展至去势抵抗状态的时间。
  • STAMPEDE的阿比特龙组和LATITUDE试验分析ADT联合阿比特龙,显示改善总生存和无进展生存。
  • ADT在耐药癌细胞中产生多种表型,包括静息、自噬和细胞衰老;衰老细胞代表一个代谢靶点,可与二甲双胍等药物协同致死。
  • 正在进行的试验正在考察新型抗雄激素药物和新药联合ADT在mHSPC患者中的效果。

临床怎么用

  • 联合治疗已成为转移性激素敏感性前列腺癌的标准治疗。
  • 理想联合方案应在个体化咨询后,结合患者整体健康和合并症状况进行选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Androgen deprivation therapy alone has been the standard of care for metastatic hormone sensitive prostate cancer for the last 75 years. This review focuses on recent trials and mechanisms which highlight the new paradigm of combining androgen deprivation therapy with other agents, changing the treatment of patients with prostate cancer who have advanced disease. MATERIALS AND METHODS: We searched the peer reviewed literature on the PubMed® and Web of Science® databases through January 2018 using the key words, "metastatic hormone sensitive prostate cancer," "metastatic castration sensitive prostate cancer," "docetaxel," "abiraterone" and "senescence in cancer." ClinicalTrials.gov was queried for ongoing studies. Relevant data recently presented at major urology and medical oncology meetings were also evaluated. RESULTS: Recently published, phase III trials using androgen deprivation therapy combinations for metastatic hormone sensitive prostate cancer can be broadly grouped into chemohormonal studies (docetaxel) or trials of androgen signaling inhibitors. The CHAARTED (Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) studies showed a survival advantage when combining androgen deprivation therapy with chemotherapy, as well as increased time to progression to castration resistant status. The abiraterone arm of the STAMPEDE and LATITUDE trials, which analyzed combining androgen deprivation therapy with abiraterone, revealed improved overall and progression-free survival. Androgen deprivation therapy generates a number of phenotypes in resistant cancer cells, including quiescence, autophagy and cellular senescence. Senescent cells represent a metabolic target for synergistic lethality with drugs such as metformin. Ongoing trials are under way to examine the effect of combining newer antiandrogens and novel drugs with androgen deprivation therapy in patients with metastatic hormone sensitive prostate cancer. CONCLUSIONS: Combination therapy has evolved as the standard of care for metastatic hormone sensitive prostate cancer. The ideal combination is tailored to patients after individualized counseling taking into account general health and comorbid illness status.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Damodaran S, Lang JM, Jarrard DF, et al. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. J Urol. 2019. PMID: 30747897. doi:10.1097/JU.0000000000000117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。